论文部分内容阅读
目的 探究骨病回生丸治疗气滞血瘀型股骨头坏死的效果.方法 将郑州中医骨伤病医院2016年1月至2017年1月,收治的80例气滞血瘀型股骨头病人,根据治疗方式的不同,将其分成对照组(骨蚀再造丸联合双氯芬酸钠缓释胶囊治疗)与观察组(骨病回生丸联合双氯芬酸钠缓释胶囊治疗)各40例,对比两组临床疗效.结果 治疗后观察组的Harris功能得分(61.32±12.01分)、SF-36表得分(77.51±6.69分),以及临床症状改善程度,要明显的优于对照组,且组间有统计学差异(P＜0.05).另外两组均为出现不良反应情况,且各项指标在正常范围内.结论 对气滞血瘀型股骨头坏死病人,给予骨病回生丸治疗,可显著改善其生存质量,且安全性高,对此值得临床应用、推广.“,”Objective To investigate the effect of bone stasis pill in treating osteonecrosis of the femoral head caused by stagnation and blood stasis.Methods In our hospital from January 2016 to January 2017,80 cases of stagnation and blood stasis type of femoral head of patients,according to the different treatment,divided into control group (bone erosion reengineering pill combined with diclofenac sodium sustained release capsules treatment) and observation group (bone retrogradation pill combined with diclofenac sodium sustained release capsules treatment) in 40 cases,compared two groups of clinical curative effect.Results The Harris score of the observation group after treatment (61.32 ± 12.01),SF-36 score (77.51 ± 6.69),and the clinical symptoms were obvious better than those of the control group,and between different groups had significant difference (P ＜ 0.05).The other two groups were adverse reactions,and all the indexes were within the normal range.Conclusion The treatment of bone stasis pill in patients with osteonecrosis of the femoral head caused by stagnation and blood stasis can significantly improve the quality of life,and the safety is high,which is worthy of clinical application and promotion.